
Orakl Oncology is a pioneering precision oncology company founded in 2023 as a spin-off from the Gustave Roussy Institute, focused on accelerating oncology drug development through a first-in-class AI-powered techbio platform. The platform integrates real-world patient data with advanced biology to create individualized patient tumor avatars that simulate drug responses, improving clinical trial success rates and patient recruitment. Orakl markets two AI-powered commercial products, O-Predict and O-Validate, which forecast patient responses and provide biological evidence for target validation, respectively. The company targets colorectal and pancreatic cancers, addressing major unmet medical needs, and aims to transform drug development by enabling better decision-making and strategic partnerships with pharmaceutical companies. Orakl has raised nearly €15 million in funding and is building a dedicated business team to support its growth and market entry.

Orakl Oncology is a pioneering precision oncology company founded in 2023 as a spin-off from the Gustave Roussy Institute, focused on accelerating oncology drug development through a first-in-class AI-powered techbio platform. The platform integrates real-world patient data with advanced biology to create individualized patient tumor avatars that simulate drug responses, improving clinical trial success rates and patient recruitment. Orakl markets two AI-powered commercial products, O-Predict and O-Validate, which forecast patient responses and provide biological evidence for target validation, respectively. The company targets colorectal and pancreatic cancers, addressing major unmet medical needs, and aims to transform drug development by enabling better decision-making and strategic partnerships with pharmaceutical companies. Orakl has raised nearly €15 million in funding and is building a dedicated business team to support its growth and market entry.
Founded: 2023 (spin‑out from Gustave Roussy)
Headquarters: Villejuif / Paris region, France
Focus: AI-powered precision oncology using patient-derived tumor avatars (organoids) and multimodal data
Products: O-Predict and O-Validate (AI commercial products)
Known funding: ≈ €14–15M across 2023–2024 (seed / pre-seed rounds)
Preclinical and clinical de-risking for oncology drug discovery and development, with initial tumor-type focus on colorectal and pancreatic cancers.
2023
Biotechnology Research
€3,000,000
Reported pre-seed/seed round
€11,000,000
Seed round with participation from multiple investors
“Singular; Bpifrance; Speedinvest; Verve Ventures; HCVC; SistaFund; Amazon Web Services”
| Company |
|---|
We are looking for a computational biologist or a computer scientist who enjoys building new computational methods and turning them into reliable production tools. You will design, implement, and maintain biomarker identification methods based on multi-omics data. You will ensure that these methods are deployable on internal and external projects and robust at scale.
This role is ideal for someone with an engineering background and a strong interest in biology, but any candidate who wants to build methods that others will use every day in production to advance cancer science is a strong fit.
Method & Algorithm Development
Production-Grade Code
Collaboration & Cross-Functional Work
Work closely with other members of the Computational Biology team to align on standards, architecture, and data models.
Collaborate with wet-lab and project teams to understand data characteristics and operational constraints.
Document methods and pipelines so that non-developers can reliably use them (clear user guides, examples, release notes).Background
MSc / Engineering degree in Computer Science, Bioinformatics, Applied Mathematics, or related field (PhD not required).
Strong interest in biology, oncology, and translational research; prior exposure to omics data is a plus.
Technical Skills
Strong programming skills in Python (and/or R), with experience developing non-trivial libraries or pipelines.
Solid understanding of software engineering practices:
Experience with data processing for omics (RNA-seq, WES/WGS, etc.) or similar large-scale numeric data.
Soft Skills
Technical Interview (45 minutes call) – A deep dive into your technical skills and expertise relevant to the role.
Technical Case (30 minutes presentation + discussion) - A case study or problem-solving exercise to assess your strategic thinking and analytical abilities. If possible this can be done in person.
Engineering Case (45-minutes presentation + discussion) - You will be presenting a piece of work you have previously worked on and which you are proud of. This will be in front of the relevant members of the Orakl Oncology team. If possible this can be done in person.
Founders Interview: As final step of our recruitment process, you will meet the founders of Orakl Oncology in person at our office. This meeting is an opportunity for the founders to assess cultural fit and ensure alignment with our company values.